Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRD - baricitinib in dermatomyositis
2024-511899-32-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Baricitinib arm with Placebo arm (2 arms). Planned start Sep 2024; status: authorised.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2024-511899-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511899-32-00.